Caribou Biosciences Inc.

Company Overview

Caribou Biosciences is a globally recognized pioneer in CRISPR genome editing and nucleic acid biology. It is a clinical-stage biopharmaceutical company that focuses on developing transformative therapies for patients with severe diseases. The company’s genome-editing platform, featuring chRDNA (CRISPR hybrid RNA-DNA) technology, allows for more precise genome editing, creating cell therapies designed to enhance activity against diseases. Caribou is advancing a pipeline of allogeneic, or off-the-shelf, cell therapies, including chimeric antigen receptor (CAR)-T and CAR-natural killer (CAR-NK) cell platforms, to provide readily available treatments.

Caribou is leveraging its transformative technology platform and discoveries in four key areas: therapeutics, agricultural biotechnology, biological research, and industrial biotechnology. The company employed 158 employees in FY 2023, with 77% focused primarily on research and development activities.

Financial Highlights (FY 2024)

Company's Business Segments

• Licensing and Collaboration Revenue : Licensing and Collaboration Revenue earned from collaboration and/or licensing agreements entered into with third parties, including related parties.